Shares of Haemonetics Co. (NYSE:HAE - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the nine research firms that are covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $108.78.
HAE has been the subject of a number of recent research reports. BTIG Research started coverage on Haemonetics in a report on Tuesday, September 10th. They issued a "buy" rating and a $112.00 target price for the company. Barrington Research reiterated an "outperform" rating and issued a $108.00 price objective on shares of Haemonetics in a report on Wednesday, December 4th. CL King started coverage on shares of Haemonetics in a research report on Friday, September 13th. They set a "buy" rating and a $116.00 target price on the stock. Bank of America began coverage on shares of Haemonetics in a research report on Wednesday, September 11th. They issued a "neutral" rating and a $85.00 price target for the company. Finally, JPMorgan Chase & Co. assumed coverage on shares of Haemonetics in a report on Friday, December 6th. They set an "overweight" rating and a $116.00 price target on the stock.
Read Our Latest Analysis on Haemonetics
Shares of Haemonetics stock opened at $75.44 on Friday. The firm has a market capitalization of $3.79 billion, a PE ratio of 31.30, a price-to-earnings-growth ratio of 1.29 and a beta of 0.38. The company has a current ratio of 3.49, a quick ratio of 2.09 and a debt-to-equity ratio of 1.39. The firm's 50 day moving average is $81.38 and its 200 day moving average is $81.35. Haemonetics has a 1 year low of $70.25 and a 1 year high of $97.97.
Haemonetics (NYSE:HAE - Get Free Report) last posted its earnings results on Thursday, November 7th. The medical instruments supplier reported $1.12 earnings per share for the quarter, topping analysts' consensus estimates of $1.09 by $0.03. Haemonetics had a net margin of 9.10% and a return on equity of 22.67%. The firm had revenue of $345.50 million for the quarter, compared to analysts' expectations of $342.57 million. During the same quarter in the previous year, the firm posted $0.99 earnings per share. The company's revenue was up 8.6% on a year-over-year basis. Equities research analysts forecast that Haemonetics will post 4.59 earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Global Alpha Capital Management Ltd. acquired a new stake in Haemonetics during the third quarter worth approximately $806,000. Loomis Sayles & Co. L P boosted its holdings in shares of Haemonetics by 8.1% during the 3rd quarter. Loomis Sayles & Co. L P now owns 163,856 shares of the medical instruments supplier's stock worth $13,171,000 after buying an additional 12,310 shares in the last quarter. BNP Paribas Financial Markets grew its position in shares of Haemonetics by 174.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 16,949 shares of the medical instruments supplier's stock worth $1,362,000 after buying an additional 10,774 shares during the period. Westfield Capital Management Co. LP increased its stake in shares of Haemonetics by 10.9% in the 3rd quarter. Westfield Capital Management Co. LP now owns 823,663 shares of the medical instruments supplier's stock valued at $66,206,000 after acquiring an additional 80,783 shares in the last quarter. Finally, FMR LLC lifted its position in shares of Haemonetics by 206.3% during the 3rd quarter. FMR LLC now owns 774,529 shares of the medical instruments supplier's stock valued at $62,257,000 after acquiring an additional 521,640 shares during the period. 99.67% of the stock is owned by institutional investors and hedge funds.
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Haemonetics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haemonetics wasn't on the list.
While Haemonetics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.